An FDA inspection of a clinical trial site usually starts with a phone call and a Form FDA 482 at the door, and it ends with either nothing in writing or a Form FDA 483 listing what the investigator got wrong. In FY 2024, 23% of the clinical investigator inspections FDA counted ended with a 483, and the findings clustered in five places: protocol compliance, case histories, adverse event reporting, investigational product records and the IRB. On September 2, 2026, four senior FDA officials wrote that the agency is expanding inspection coverage, looking harder at early-phase trials and making more inspection findings public. Their post is about sites outside the United States, but the standard it restates, in its words, "holds whether a trial was conducted in Boston or Beijing." A site that can produce clean records for those five themes on a day's notice is ready. One that needs a week to find them is not.
In short
- FDA final-classified 609 clinical investigator inspections in FY 2024: 484 No Action Indicated, 110 Voluntary Action Indicated, 15 Official Action Indicated (FDA BIMO metrics).
- Official Action Indicated classifications rose from 5 in 2020 and 2021 to 15 in 2024.
- Of 692 investigator inspections in FDA's FY 2024 483 trend review, 156 (23%) ended with a Form FDA 483.
- FDA encourages a written 483 response within 15 U.S. business days of the inspection's end (FDA guidance, December 2025).
What FDA said on September 2, 2026
The FDA Voices post, signed by four senior officials across FDA's drug, biologics, device and oncology centres, lists five actions. FDA is "adding resources for foreign Bioresearch Monitoring (BIMO) inspections," including "inspecting more phase 1 and early-stage trials"; it is being "more systematic" about telling sponsors when sites, people or documents were not available for inspection; it is training reviewers to spot sites of concern; it will make more inspection findings public where it finds human subject protection or data integrity problems abroad; and it will look harder at studies run outside an IND or IDE.
The reason given is blunt: audits "across trial phases" have found "fabricated participants, falsified health conditions, falsified laboratory results, and concealed adverse events."
Nothing in the post changes the rules for a Michigan site. What it changes is attention. A sponsor reading it will want its US sites to be the ones with nothing to hide and everything to hand, and a site that has just joined early-phase work under the FDA Expedited IND pilot should expect the early-phase scrutiny FDA describes abroad to shape what sponsors ask of it at home.
How an FDA inspection of a clinical trial site runs
FDA's final guidance on bioresearch monitoring inspections, issued in December 2025, withdrew the June 2010 information sheet on FDA inspections of clinical investigators; an SOP that still cites it needs updating. Its main points for an investigator site:
| Stage | What the December 2025 guidance says |
|---|---|
| Notice | FDA "generally pre-announces" domestic inspections, by phone; it may not, if notice "may impact the inspection" |
| No reply | A site's failure to acknowledge the call "should not be a reason to delay the start" |
| Arrival | Form FDA 482 issued and credentials shown to the top official or onsite designee |
| Records | Sites with electronic systems "should be prepared to provide access to FDA personnel upon their arrival" |
| Closeout | Findings discussed; a Form FDA 483 issued if appropriate |
| Response | Not required, but encouraged "within fifteen (15) U.S. business days" |
| Outcome | Classified No Action, Voluntary Action or Official Action Indicated; FDA "publicly posts the final inspection classification" |
The legal floor sits in 21 CFR 312.68: an investigator must let an authorised FDA officer, "at reasonable times," access, copy and verify the records and reports kept under 312.62.
What FDA cited at clinical sites in FY 2024
FDA's FY 2024 observation trends for clinical investigators name five themes, each tied to a regulation:
- Protocol compliance (312.60). The most frequent findings: study procedures performed incorrectly or missed, inclusion criteria not met, exclusion criteria met, missed assessments, and investigational product overdosed or not held. Out-of-window visits and missed visits are on the list too, which is why the missed visit is a retention problem and an inspection problem at once.
- Accurate and adequate case histories (312.62(b)). Led by data discrepancies and records that were not contemporaneous, then missing data and records not maintained.
- Adverse events reported late or not at all to the sponsor (312.64(b)).
- Investigational product accountability (312.62(a)). Missing returns and dispositions, missing use by subject, and wrong or missing quantities.
- The IRB (312.66). FDA marked two findings as new in FY 2024: prompt reporting of changes in research to the IRB, and progress reports not submitted or an IRB approval lapsing.
How a site prepares, in the order FDA looks
- Name who takes the call. The pre-announcement comes by phone and does not wait for a reply. Put the name of the person who answers it, and a deputy, in the SOP, with the list of who must be told the same day: the investigator, the sponsor, the IRB.
- Rehearse the first hour. Who receives the 482, which room the investigator works in, and who can give read access to the EDC, eTMF and eISF on arrival. FDA says to be ready for electronic access "upon their arrival," not after IT is found.
- Check eligibility files first. Two of FDA's top protocol findings are eligibility: inclusion not met, exclusion met. For every enrolled participant, the source that shows each criterion was checked before randomisation should be findable in minutes.
- Reconcile the product. Match dispensing, returns and destruction to participants and dates. Missing dispositions and quantities are FDA's leading accountability findings.
- Walk the IRB timeline. Every amendment approved before it was implemented, every progress report filed, no approval lapse. These are the new findings; the regulatory binder calendar is where the expiry dates live.
- Draft the 483 response template now. One section per observation, agree or disagree with reasons, corrective and preventive actions with dates, how you will check they worked, and the evidence attached. FDA also asks for "a commitment from senior leadership." Fifteen business days is short if the template does not exist.
The mistake most sites make at step 6
They answer the observation instead of the cause. A 483 item about a late adverse event report is not fixed by filing the report; FDA's guidance asks for corrective and preventive actions and "a method of verifying or monitoring the effectiveness of the actions." If the cause was that nobody reviewed visit notes for adverse events within a set time, the response names the new review step, the training record and the date the first check was done.
What we build for this
For sites on the clinical research industry page, we build monitoring visit preparation that assembles the pre-visit checklist from the monitoring plan, listing source expected since the last visit, open queries, regulatory items due and deviations to log, so what is missing reaches the coordinator in time. We also build regulatory document tracking across studies and staff, with escalating reminders and missing-document flags. Neither one is a system of record, certifies compliance or decides anything about a participant; the binder, the EDC and the investigator stay in charge. The value on inspection day is that the lists already exist.
An inspector's first request is usually a record. The site that hands it over in minutes has already answered the second question.
